A new position paper on Medication Related Osteonecrosis of the Jaw (MRONJ) released by the American Association of Oral and Maxillofacial Surgeons expands the scope of the condition previously referred to as Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) and changes its name to reflect the antiresorptive (denosumab) and antiangiogenic therapies that have recently been associated with the condition.
In addition to changing the name of the condition, the MRONJ position paper
provides guidance to:
1. physicians, dentists, dental specialists, and patients in making medical decisions relating
to the risk of developing MRONJ, as well as the risks and benefits of those
medications related to osteonecrosis of the jaw (ONJ);
2. clinicians regarding diagnosis of MRONJ in patients with a history of exposure to
antiresorptive and/or antiangiogenic agents; and to
3. clinicians regarding MRONJ prevention measures and management strategies for patients with
MRONJ, based on their disease stage.
MRONJ appears as a non-healing exposed bone in the mouth and may affect patients undergoing intravenous cancer-related therapy, or more rarely, patients treated with oral or IV bisphosphonates for osteoporosis.
Click below for a pdf of the paper regarding this difficult condition: